Amir T. Fathi MD [slides]- IDH 1/2-Mutant AML Treatment Acute Myelogenous Leukemia 1 Min Read7 Amir T. Fathi MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital Join…
INDIGO Trial Results: Vorasidenib Shows Promising Efficacy for IDH-Mutant Low-Grade Glioma Acute Lymphoblastic Leukemia 3 Mins Read1 Dr. Timothy Cloughesy, a prominent physician from UCLA Health, conducted the INDIGO clinical trial to evaluate the efficacy of Vorasidenib,…
